Valuing the effect sizes hypothesized in phase 3 trials of targeted therapies in oncology by Reilly, G, Wise, A, Attwood, S, Scudder, C, Love, S

The changing world of clinical trials 2003-2017: A view from the AspECT trial by Reilly, G, Love, S, Wise, A, Scudder, C, Jankowski, J, Attwood, S

Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial by Marcovecchio, ML, Wicker, LS, Dunger, DB, Dutton, SJ, Kopijasz, S, Scudder, C, Todd, JA, Johnson, PRV

CAPECITABINE (CAPE) +/- BEVACIZUMAB (BEV) IN THE ADJUVANT TREATMENT OF COLORECTAL CANCER (CRC) FIRST AND FINAL TOXICITY RESULTS FROM THE INTERNATIONAL PHASE III QUASAR2 TRIAL by Midgley, R, Love, S, Potter, V, Segelov, E, Ferry, DR, Weaver, A, Scudder, C, Julier, P, Grumett, S, Kerr, D

Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial by Urbonas, V, Schadendorf, D, Zimmer, L, Danson, S, Marshall, E, Corrie, P, Wheater, M, Plummer, E, Mauch, C, Scudder, C, Goff, M, Love, S, Mohammed, S, Middleton, M

General population screening for type 1 diabetes using islet autoantibodies at the preschool vaccination visit: a proof-of-concept study (the T1Early study) by Scudder, C, Townson, J, Bowen-Morris, J, Gillespie, K, Evans, P, Jones, S, Thomas, NPB, Stanford, J, Fox, R, Todd, JA, Greenfield, S, Dayan, CM, Besser, REJ

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial by Kerr, R, Love, S, Segelov, E, Johnstone, E, Falcon, B, Hewett, P, Weaver, A, Church, D, Scudder, C, Pearson, S, Julier, P, Pezzella, F, Tomlinson, I, Domingo, E, Kerr, D

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial by Love, S, Kerr, R, Segelov, E, Johnstone, E, Falcon, B, Hewett, P, Weaver, A, Church, D, Scudder, C, Pearson, S, Julier, P, Pezzella, F, Tomlinson, I, Domingo, E, Kerr, D

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. by Rosmarin, D, Palles, C, Church, D, Domingo, E, Jones, A, Johnstone, E, Wang, H, Love, S, Julier, P, Scudder, C, Nicholson, G, Gonzalez-Neira, A, Martin, M, Sargent, D, Green, E, McLeod, H, Zanger, U, Schwab, M, Braun, M, Seymour, M, Thompson, L, Lacas, B, Boige, V, Ribelles, N, Afzal, S

A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. by Rosmarin, D, Palles, C, Pagnamenta, A, Kaur, K, Pita, G, Martin, M, Domingo, E, Jones, A, Howarth, K, Freeman-Mills, L, Johnstone, E, Wang, H, Love, S, Scudder, C, Julier, P, Fernández-Rozadilla, C, Ruiz-Ponte, C, Carracedo, A, Castellvi-Bel, S, Castells, A, Gonzalez-Neira, A, Taylor, J, Kerr, R, Kerr, D, Tomlinson, I

A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS by Rosmarin, D, Palles, C, Pagnamenta, A, Kaur, K, Pita, G, Martin, M, Domingo, E, Jones, A, Howarth, K, Freeman-Mills, L, Johnstone, E, Wang, H, Love, S, Scudder, C, Julier, P, Fernández-Rozadilla, C, Ruiz-Ponte, C, Carracedo, A, Castellvi-Bel, S, Castells, A, Gonzalez-Neira, A, Taylor, J, Kerr, R, Kerr, D, Tomlinson, I

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial by Iveson, T, Kerr, R, Saunders, M, Cassidy, J, Hollander, N, Tabernero, J, Haydon, A, Glimelius, B, Harkin, A, Allan, K, McQueen, J, Scudder, C, Boyd, K, Briggs, A, Waterston, A, Medley, L, Wilson, C, Ellis, R, Essapen, S, Dhadda, A, Harrison, M, Falk, S, Raouf, S, Rees, C, Olesen, R, Propper, D, Bridgewater, J, Azzabi, A, Farrugia, D, Webb, A, Cunningham, D, Hickish, T, Weaver, A, Gollins, S, Wasan, H, Paul, J